Geron Corporation

NASDAQ:GERN

Biotechnology

Healthcare
$0.99 +4.07%

+$0.05 today

Market cap
$638.38M
Beta
0.60
P/E (TTM)
-12.3
EPS (TTM)
-$0.10
52W Low $1.04High $2.01

Volume 34.97M

Average 16.28M

GERN Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Geron CorporationNASDAQ: GERN

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin widens to -0.5%

Operating margin was -0.5% in Q1 FY2026, up 41.7 pp from a year earlier. On a trailing-twelve-month basis it was -19.1%, up 96.4 pp year over year. Over 3 fiscal years it widened by 23217.4 pp.

Context

  • Operating margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 4 analysts of 4.0% for the fiscal year ending Dec 2026, up from -29.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-0.5%+22.0 pp QoQ
Last fiscal yearDec 2025
-29.3%+196.4 pp YoY
LTMMar 2026
-19.1%+96.4 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+41.7 pp+27.5 pp-14.2 pp
1 year+196.4 pp+33.3 pp-163.1 pp
3 years+23217.4 pp+59.6 pp-23157.7 pp
5 years+89.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-29.3%
Year-over-year change
+196.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How GERN compares with its peers on the latest reported figures

  • GERN's LTM Mar 2026 operating margin of -19.1% is the lowest of the 5 companies compared; the peer median is 29.4%.
  • Its year-over-year change of +96.4 pp is the 2nd highest of 4, against a peer median of +19.9 pp.
  • Over three fiscal years its change of +23217.4 pp compares with a peer median of +48.8 pp.
GERN Competitors Peer median
Operating Margin for GERN and competitors
Company Period LTM level YoY 3-year change
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202641.6% +19.9 pp+88.8 pp
INCYIncyte CorporationLTM Jun 202631.6% +10.4 pp+8.7 pp
ATNMActinium Pharmaceuticals, Inc.LTM Jun 202627.2% —-36963.4 pp
IPSCCentury Therapeutics, Inc.FY2025-13.8% +2082.7 pp+2560.4 pp
GERNGeron CorporationLTM Mar 2026-19.1% +96.4 pp+23217.4 pp
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025— ——
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
DMRADamora Therapeutics, Inc.FY2025— ——
Peer median (excluding GERN) 29.4%+19.9 pp+48.8 pp

Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.39M596K237K76.99M183.88M
Cost of Revenue0001.26M4.75M
Gross Profit1.39M596K237K75.74M179.14M
Gross Margin100.0%100.0%100.0%98.4%97.4%
Research & Development85.73M95.52M125.05M103.74M73.72M
Selling, General & Admin29.67M43.63M69.14M145.73M159.26M
Operating Expenses115.39M139.15M194.18M249.47M232.97M
Depreciation & Amortization783K868K1.03M1.22M1.2M
EBITDA(111.59M)(134.15M)(174.78M)(154.85M)(51.92M)
EBITDA Margin-8010.7%-22508.6%-73747.7%-201.1%-28.2%
Operating Income(114M)(138.55M)(193.94M)(173.73M)(53.84M)
Operating Margin-8183.7%-23246.6%-81832.9%-225.6%-29.3%
Interest Income527K2.53M18.15M19.61M18.12M
Interest Expense3.74M6.88M8.31M18.5M32.66M
Other Income / Expenses(2.11M)(3.35M)9.82M(840K)(31.95M)
Income Before Tax(116.11M)(141.9M)(184.13M)(174.57M)(85.78M)
Pre-Tax Margin-8335.4%-23808.9%-77690.7%-226.7%-46.7%
Income Tax Expense00000
Net Income(116.11M)(141.9M)(184.13M)(174.57M)(85.78M)
Net Margin-8335.4%-23808.9%-77690.7%-226.7%-46.7%
EPS (Basic)(0.37)(0.37)(0.32)(0.27)(0.13)
EPS (Diluted)(0.37)(0.37)(0.32)(0.27)(0.13)
Weighted Avg Shares327.63M380.78M570.65M646.03M666.66M
Weighted Avg Shares (Diluted)327.63M380.78M570.65M646.03M666.66M

Geron Corporation

NASDAQ:GERN

Intrinsic Alpha fair value

Locked

Current Price

$0.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.